"Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease

[1]  D. G. Gorman,et al.  Creutzfeldt‐Jakob disease in a pathologist , 1992, Neurology.

[2]  M. Palmer,et al.  Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease , 1991, The Lancet.

[3]  T. Miyatake,et al.  Creutzfeldt‐Jakob disease in a patient with a cadaveric dural graft , 1991, Neurology.

[4]  A. Buescu,et al.  Pituitary growth hormone and Creutzfeldt-Jakob disease. , 1991, BMJ.

[5]  P. Beauvais,et al.  Creutzfeldt-Jakob disease in children treated with growth hormone , 1991, The Lancet.

[6]  M. Preece,et al.  Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. , 1991, BMJ.

[7]  D. Wysowski,et al.  Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. , 1991, JAMA.

[8]  P. Blumbergs,et al.  Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. , 1990, Australian and New Zealand journal of medicine.

[9]  G. Macchi,et al.  Transmission of Creutzfeldt-Jakob disease by dural cadaveric graft. , 1989, Journal of neurosurgery.

[10]  R. Kalb,et al.  Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. Case report. , 1988, Journal of neurosurgery.

[11]  C. Merril,et al.  Creutzfeldt‐Jakob disease following pituitary‐derived human growth hormone therapy , 1988, Neurology.

[12]  E. Hedley‐Whyte,et al.  Preclinical Creutzfeldt‐Jakob disease discovered at autopsy in a human growth hormone recipient , 1988, Neurology.

[13]  P. Brown,et al.  A new case of Creutzfeldt‐Jakob disease associated with human growth hormone therapy in New Zealand , 1988, Neurology.

[14]  E. Hedley‐Whyte,et al.  Neuropathologic verification of Creutzfeldt‐Jakob disease in the exhumed American recipient of human pituitary growth hormone , 1986, Neurology.

[15]  J. Parisi,et al.  Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone. , 1985, The New England journal of medicine.

[16]  B. Berg,et al.  Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. , 1985, The New England journal of medicine.

[17]  M. Preece,et al.  CREUTZFELDT-JAKOB DISEASE AFTER ADMINISTRATION OF HUMAN GROWTH HORMONE , 1985, The Lancet.

[18]  R. Will,et al.  Evidence for case-to-case transmission of Creutzfeldt-Jakob disease , 1982, Journal of neurology, neurosurgery, and psychiatry.

[19]  C. Masters,et al.  Transmissible spongiform encephalopathy (Creutzfeldt-Jakob disease). Atypical clinical and pathological findings. , 1981, Archives of neurology.

[20]  D. Gajdusek,et al.  DANGER OF ACCIDENTAL PERSON-TO-PERSON TRANSMISSION OF CREUTZFELDT-JAKOB DISEASE BY SURGERY , 1977, The Lancet.

[21]  A. Devoe,et al.  Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease. , 1974, The New England journal of medicine.

[22]  H. Markus,et al.  Creutzfeldt-Jakob disease in recipients of human growth hormone in the United Kingdom: a clinical and radiographic study. , 1992, The Quarterly journal of medicine.

[23]  G. Macchi,et al.  Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. , 1991, Hormone research.

[24]  Dc Miller,et al.  Creutzfeldt-Jakob disease in histopathology technicians. , 1988, The New England journal of medicine.